Biotech Investment Analyst

Overview

This part-time contract role involves evaluating biotech companies, commercial drugs, and drug-development programs from an investment perspective. The work focuses on clinical data, mechanisms of action, competitive positioning, value drivers, and the strength of investment theses.

The engagement begins with a short paid pilot and may lead to recurring work as the project expands.

Responsibilities

• Create and critique rubrics for evaluating commercial drugs and drug-development programs.
• Assess companies and drug assets across:
  • Mechanism of action
  • Clinical data
  • Competitive position
  • Key value drivers
• Evaluate the strength and quality of investment-style theses.
• Identify weak, overconfident, unsupported, or missing assumptions.
• Conduct end-to-end assessments of assigned biotech companies and their drug assets.
• Apply investment expertise across approximately 5–10 companies during the pilot.

Requirements

• US-based biotech or healthcare investment analyst with specialist-fund experience.
• 5+ years of experience evaluating biotech or pharmaceutical companies and/or drug assets.
• Strong familiarity with biotech and pharmaceutical development programs.
• Demonstrated ability to assess drug assets and the companies behind them from an investment perspective.
• Strong understanding of clinical development, competitive positioning, and biotech value drivers.
• Ability to critically evaluate investment assumptions and theses.

Engagement Details

• Position type: Part-time contract
• Format: Fully remote
• Location: Remote — United States
• Initial engagement: Approximately 10–20 hours
• Pilot duration: 1–2 weeks
• Schedule: Flexible, subject to project requirements
• Contract: Independent contractor
• Potential: Recurring opportunities for strong contributors

Compensation & Benefits

• Compensation: $120–$200/hour
• Payments are made weekly through Stripe or Wise based on services rendered.
• Projects may be extended, shortened, or concluded early based on project needs and performance.
• Work will not involve access to confidential or proprietary information from any employer, client, or institution.
• H1-B and STEM OPT candidates cannot be supported at this time.
• Opportunity to apply biotech investment expertise to emerging AI evaluation work.
• Opportunity to contribute to expert-level assessment of pharmaceutical drugs, development programs, biotech companies, and drug assets.
• Potential for continued engagement as the work scales.

Equal Opportunity

All qualified applicants are considered without regard to legally protected characteristics. Reasonable accommodations are provided upon request.

Desired Skills and Experience

• Evaluation
• Investment analysis